Lutz Jermutus is a Product Development Team Leader and Senior Director, R&D, in MedImmune’s Cardiovascular & Metabolic Diseases iMED, responsible for leading clinical drug candidates from late stage pre-clinical through IND to clinical proof-of-concept. He was previously the global head of technology overseeing teams in the UK and US. In this role, he was leading non-antibody biologics technologies and resulting drug projects across all disease areas. Key activities included therapeutic peptides and proteins but also novel biologics modalities such as polyclonal antibodies, antibody-drug-conjugates, multi-functional antibodies, scaffolds and oligonucleotides. His team established a phenotypic selection and screening platform that delivered novel therapeutic targets across all disease areas and managed multiple technology collaborations with biotechs including Evotec, Direvo Biotech, PeptiDream, Molecular Partners, Silence Therapeutics, Xenome and Retrogenix. Previously at Cambridge Antibody Technology, Lutz was director of discovery, oncology, and director of protein engineering.
Following studies in chemical engineering in Karlsruhe (Germany) and biotechnology in Strasbourg (France), Lutz earned his doctorate at the University of Zurich (Switzerland) in biochemistry. He was a Kekulé-Fellow of the German Chemical Industry Association, a recipient of a fellowship at the German National Academic Foundation and in 2009 was admitted as Fellow of the Royal Society of Chemistry. In 2013, he was elected Industrial Fellow at Trinity Hall, University of Cambridge.

Lutz has published widely in the area of protein science and engineering, and is an inventor on numerous product (eg. tralokinumab, fresolimumab) and technology patents.

NanoChemBio is a multidisciplinary research team lead by Dr. Rosario M. Sánchez-Martín that focussed its research on the design and development of therapeutic and diagnosis strategies with a clear translation outcome. Rosario has developed her research career between the UK and Spain. She spent 10 years in the UK, firstly as postdoctoral fellow at the University of Southampton and later, in 2006, as independent researcher at the University of Edinburgh. In January 2011, she moved to the University of Granada where she works on transferring her expertise and know-how in designing and developing nanotechnology-based platforms. From 2012, her research team is located at the Centre for Genomics and Oncological Research (GENyO). Nowadays, her research activity is focussed on the development of nanotechnology based platform for diagnosis and personalised medicine.

Dr. Hale is presently at Ensemble Therapeutics as SVP of Biological Sciences. Dr. Hale leads Ensembles oncology-focused preclinical pipeline and is one of the architects of the corporate strategy to explore peptidic macrocycles as therapeutics against hard-to-drug protein:protein interaction targets. Prior to Ensemble, Dr. Hale was most recently at Praecis Pharmaceuticals and was a key inventor of the DNA-Encoded Library drug discovery platform that facilitated the acquisition of Praecis Inc. by GlaxoSmithKline plc. He received his Ph.D in biochemistry from the University of Maryland under Professor John Gerlt and was a NIH post-doctoral fellow at MIT under Professor Paul Schimmel.

Dr Juan J. Diaz-Mochon is a Ramon and Cajal Fellow based at the University of Granada and specialised on chemical biology and bioenterprise. He worked in the UK for 10 years with Prof. Mark Bradley before moving to Granada to work at the Centre for Genomics and Oncological Research (GENYO). He is also the founder and CSO of DestiNA Genomics Ltd, a spin-off of the University of Edinburgh, and the inventor of its core technology. He has enjoyed a distinguished academic career in Spain, Italy, and in the UK.
 

Lutz Jermutus is a Product Development Team Leader and Senior Director, R&D, in MedImmune’s Cardiovascular & Metabolic Diseases iMED, responsible for leading clinical drug candidates from late stage pre-clinical through IND to clinical proof-of-concept. He was previously the global head of technology overseeing teams in the UK and US. In this role, he was leading non-antibody biologics technologies and resulting drug projects across all disease areas. Key activities included therapeutic peptides and proteins but also novel biologics modalities such as polyclonal antibodies, antibody-drug-conjugates, multi-functional antibodies, scaffolds and oligonucleotides. His team established a phenotypic selection and screening platform that delivered novel therapeutic targets across all disease areas and managed multiple technology collaborations with biotechs including Evotec, Direvo Biotech, PeptiDream, Molecular Partners, Silence Therapeutics, Xenome and Retrogenix. Previously at Cambridge Antibody Technology, Lutz was director of discovery, oncology, and director of protein engineering.
Following studies in chemical engineering in Karlsruhe (Germany) and biotechnology in Strasbourg (France), Lutz earned his doctorate at the University of Zurich (Switzerland) in biochemistry. He was a Kekulé-Fellow of the German Chemical Industry Association, a recipient of a fellowship at the German National Academic Foundation and in 2009 was admitted as Fellow of the Royal Society of Chemistry. In 2013, he was elected Industrial Fellow at Trinity Hall, University of Cambridge.

Lutz has published widely in the area of protein science and engineering, and is an inventor on numerous product (eg. tralokinumab, fresolimumab) and technology patents.

Ali is a Reader in chemical biology at the University of Southampton in the UK. Ali leads an interdisciplinary team of scientists whose efforts are focused on the development of novel chemical tools that enable new insight into the role of protein-protein interactions in cell biology, and as the starting point for new therapeutics. Research highlights include two first in class inhibitors of transcription factor assembly (JACS, 2013, 10418 and Chem. Sci. 2013, 3046), and the development of a biocompatible, non-natural DNA backbone-linker (with Prof. Tom Brown; PNAS, 2011, 11338 and Angew. Chem. 2014, 2362).

Mark Howard has been at the University of Kent for 14 years and has interests in peptides, proteins, pathway intermediates and metabolomics. His peptide interests include the structural investigations of peptides involved in the recognition of integrins, bacterial microcompartments and viruses. Mark began his interest in NMR spectroscopy at Aston University, Birmingham where he gain both BSc and PhD in Chemistry before moving to Cambridge and beginning his career as a biological NMR specialist working on pyruvate dehydrogenase complex. He held senior NMR roles with the MRC and GE Healthcare before moving to Kent in 2001.

Lutz Jermutus is a Product Development Team Leader and Senior Director, R&D, in MedImmune’s Cardiovascular & Metabolic Diseases iMED, responsible for leading clinical drug candidates from late stage pre-clinical through IND to clinical proof-of-concept. He was previously the global head of technology overseeing teams in the UK and US. In this role, he was leading non-antibody biologics technologies and resulting drug projects across all disease areas. Key activities included therapeutic peptides and proteins but also novel biologics modalities such as polyclonal antibodies, antibody-drug-conjugates, multi-functional antibodies, scaffolds and oligonucleotides. His team established a phenotypic selection and screening platform that delivered novel therapeutic targets across all disease areas and managed multiple technology collaborations with biotechs including Evotec, Direvo Biotech, PeptiDream, Molecular Partners, Silence Therapeutics, Xenome and Retrogenix. Previously at Cambridge Antibody Technology, Lutz was director of discovery, oncology, and director of protein engineering.
Following studies in chemical engineering in Karlsruhe (Germany) and biotechnology in Strasbourg (France), Lutz earned his doctorate at the University of Zurich (Switzerland) in biochemistry. He was a Kekulé-Fellow of the German Chemical Industry Association, a recipient of a fellowship at the German National Academic Foundation and in 2009 was admitted as Fellow of the Royal Society of Chemistry. In 2013, he was elected Industrial Fellow at Trinity Hall, University of Cambridge.

Lutz has published widely in the area of protein science and engineering, and is an inventor on numerous product (eg. tralokinumab, fresolimumab) and technology patents.

Renata has experience in drug discovery, the design and synthesis of peptides, and conjugation methods.
She carried out post-doctoral research in the USA at the University of Massachusetts and Stanford University, and then worked as a research scientist at Amylin Pharmaceuticals in their peptide drug research group.
Prior to joining Haemostatix, Renata worked in antibody drug formulation at Medimmune.
She has an MSc and PhD in organic chemistry from the University of Wroclaw, Poland
 

Roger New studied chemistry at Oxford and obtained a PhD in immunology at St Mary’s Hospital, London, before going to work in Liverpool for 14 years, first at the Department of Biochemistry, then at the School of Tropical Medicine and Hygiene. His research activities have centred on the use of drug delivery systems (particularly liposomes) to improve the therapy of disease, during which time he has devised patented approaches to oral peptide delivery, vaccine carrier systems, and a technology for discovery of new therapeutics. He has acted as expert advisor in numerous institutions at home and overseas, has written a textbook on liposomes, and is honorary Reader in Pharmaceutics at Kings College London. Dr New’s laboratory was the first to demonstrate the in vivo efficacy of liposomal amphotericin in leishmaniasis, a product which has now been commercialised for over ten years. He went into industry fifteen years ago, first in Biocompatibles Ltd, then Cortecs, and is currently Co-founder and Executive Director of the biotech R&D company Proxima Concepts Ltd, with laboratories located at the London Bioscience Innovation Centre. Development of the peptide delivery technology invented by Dr New has resulted in products for oral administration of PTH, calcitonin and insulin, now in Phase II clinical trials, and licensed to large pharma in an emerging market. The discovery technology has yielded a peptide which is currently undergoing preclinical studies as a treatment for rheumatoid arthritis.

Dr Chiara Valenzano is a Principal Scientist at UCB in the department of Primary Pharmacology. She completed her studies in synthetic organic chemistry in Italy, to then move to the USA to pursue a PhD at Brown University, centred on studying the biosynthesis of polyketide antibiotics. In 2011, she was awarded a Marie Curie International Incoming fellowship to work at the University of Cambridge. The focus of her research, ever since, has been the development of small molecules and peptides to disrupt protein-protein interactions.

Following PhD with MLH Green (Oxford, 1991), Scott was a Royal Society European Fellow with H-H Brintzinger (Konstanz) then joined the group of FGN Cloke (Sussex) where he was awarded a Ramsay Fellowship and a lectureship. He was promoted to professor at Warwick in 2004. His research interests are in metal-mediated catalysis and self-assembly with applications in materials and more recently medicine.
 

Having completed his D.Phil at Oxford University in late 2001, Dr Mason spent six years abroad, in Germany and then France, developing his research skills and learning how biophysical methods can be best applied to understand peptide-membrane interactions in a cellular context. Dr Mason returned in 2007 and, at King’s College London, undertakes both basic and translational research supported by multidisciplinary chemical, computational, biophysical and biological techniques. These techniques yield mechanistic insights, intractable by other methods, which are exploited to generate novel, potentially clinically relevant, peptide materials in the fields of bacterial and parasitic infection and nucleic acid delivery.

David Brayden is Professor of Advanced Drug Delivery at University College Dublin (UCD) and is also a Fellow of the UCD Conway Institute. He has a Ph.D. in Pharmacology from the University of Cambridge, UK (1989). Following a postdoc at Stanford University, he joined Elan Corporation and became a senior scientist (1991-2001). He then joined UCD as a lecturer in veterinary pharmacology (2001) and was appointed full Professor in 2014. He was Director of the Science Foundation Ireland (SFI) Research Cluster (The Irish Drug Delivery Research Network) from 2007-2013, and is a co-lead PI on the SFI Centre in Medical Devices (CURAM) (2014-2020). He is the author or co-author of more than 200 research publications and patents. He has served on the Controlled Release Society (CRS) Board of Scientific Advisors (2006-2009) and was made a CRS Fellow in 2012.